• Siltuximab for patients diagnosed with severe respiratory complications due to COVID-19
• Anti-IL-6 mitigation of cytokine storm • Observational retrospective cohort study
• Cohort A: continuous positive airway pressure followed by siltuximab
• Cohort B: intubation followed by siltuximab
• Control group receiving continuous positive airway pressure or intubation only
•  N = 220
• Primary outcome of mortality over 30 days • Detailed siltuximab dosing regimen not specified.
• Treatment procedure was based on clinicians judgement
• Study completed May 8, 2020. Results pending (NCT04322188, 2020)